#Acutis diagnostics and cigna series#

Additionally, UTIs are a leading cause of infection-related hospitalization events in the elderly population. In the US, they account for over 10 million office visits, 3 million Emergency Department encounters and half a million hospitalizations, at a total cost of over $6 billion to the healthcare system yearly.

Impacting more than 150 million individuals each year, urinary tract infections (UTI) are the second most common infection observed globally. The current pandemic has placed a bright spotlight on companies in the infectious disease market, and the ability for our R&D team to be the first in the nation to successfully go through the rigorous process of a New York approval illustrates the high scientific standards that we employ,' says Acutis CEO, Jibreel Sarij. 'This is a tremendous milestone as we expand our infectious disease footprint.

With approval from the New York State Department of Health, Acutis will become the first laboratory that is able to offer such testing in all 50 states. Based on a custom designed microarray, the Reveal™ UTI can simultaneously test for the presence of 31 bacteria and fungi that are among the most common pathogens associated with such infections. 25, 2020 /PRNewswire-PRWeb/ - Acutis Diagnostics, a vertically integrated company serving the medical and pharmaceutical communities by providing rapid and reliable diagnostic insights that impact clinical decisions in infectious disease, announced today that it has received approval from the New York State Department of Health for its Acutis Reveal™ Urinary Tract Infection molecular assay.

#Acutis diagnostics and cigna series#

Sophia has formed a series of partnerships to embed DDM into molecular tests, including recent ones with Agilent Technologies and with the Synergy Oncology division of Synergy Laboratories for a new tumor profiling assay.HICKSVILLE, N.Y., Sept. 'Additionally, the test is to provide researchers with a robust set of data and insights to support clinical decision-making and future research.' 'The use of Sophia DDM will help us quickly launch this new assay to aid clinical researchers in speeding up the process for launching select clinical oncology trials and ensuring the most appropriate patients are enrolled,' Acutis CSO and Executive VP Abdel Halim said in a statement. The new product will also support retrospective analysis to explain clinical outcomes and assist in target discovery. Under the new collaboration, Hicksville, New York-based Acutis will combine Sophia's DDM for Hereditary Cancers module with its own laboratory analysis technologies to create a next-generation sequencing test to screen patients for eligibility in clinical trials. NEW YORK – Sophia Genetics said Tuesday that Acutis Diagnostics will incorporate the Sophia DDM analytics platform into a new genomic assay to support clinical research and therapeutic development for hereditary cancers. Advances in Clinical Genomics Profiling.